Focusing on partnership model for MicroDose-MN and MacroDose-MN patches to deliver psychedelics. Creating value and intellectual property protection for psychedelic programs. Providing pathways for partners to enter FDA Phase 1 and 2 clinical studies in 2022 with psychedelics. TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE…


Previous articleU.S. FDA Approves Nova Mentis Orphan Drug Application
Next articleCOMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder